<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7344926\results\search\disease\results.xml">
  <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The Coronavirus" exact="Disease" post="2019 (COVID-19), caused by the severe acute respiratory syndrome"/>
  <result pre="Abstract The Coronavirus Disease 2019 (COVID-19), caused by the severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2), outbreak from Wuhan City, Hubei"/>
  <result pre="The Coronavirus Disease 2019 (COVID-19), caused by the severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2), outbreak from Wuhan City, Hubei province,"/>
  <result pre="Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2), outbreak from Wuhan City, Hubei province, China"/>
  <result pre="global health emergency. The emerging virus, SARS-CoV-2, causes coughing, fever," exact="muscle" post="ache, and shortness of breath or dyspnea in symptomatic"/>
  <result pre="fever, muscle ache, and shortness of breath or dyspnea in" exact="symptomatic" post="patients. The pathogenic particles that are generated by coughing"/>
  <result pre="digital tracking machine learning pandemic policy 1. Introduction The Coronavirus" exact="Disease" post="2019 (COVID-19), caused by the novel coronavirus strain, known"/>
  <result pre="caused by the novel coronavirus strain, known as the severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in 2019 and is"/>
  <result pre="by the novel coronavirus strain, known as the severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2), emerged in 2019 and is considered"/>
  <result pre="the novel coronavirus strain, known as the severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2), emerged in 2019 and is considered to"/>
  <result pre="is considered to be a pandemic in the form of" exact="viral pneumonia" post="[1]. In the last two decades, there have been"/>
  <result pre="considered to be a pandemic in the form of viral" exact="pneumonia" post="[1]. In the last two decades, there have been"/>
  <result pre="World Health Organization (WHO) declares COVID-19 to be outbreaks of" exact="infectious disease" post="crossing international boundaries, resulting in morbidity and mortality at"/>
  <result pre="Health Organization (WHO) declares COVID-19 to be outbreaks of infectious" exact="disease" post="crossing international boundaries, resulting in morbidity and mortality at"/>
  <result pre="[3]. Well-planned public health structures, such as the Centers for" exact="Disease" post="Control and Prevention (CDC) and societal policies are needed"/>
  <result pre="COVID-19 pandemic. Herein, we discuss the biological basis of the" exact="disease" post="progression and transmission routes, along with the historical background"/>
  <result pre="and transmission routes, along with the historical background of similar" exact="viral" post="infections. Similarities and differences between the novel SARS-CoV and"/>
  <result pre="to pay enough attention until the outbreak of the severe" exact="acute" post="respiratory syndrome (SARS) coronavirus (SARS-CoV) [4]. SARS-CoV is one"/>
  <result pre="pay enough attention until the outbreak of the severe acute" exact="respiratory" post="syndrome (SARS) coronavirus (SARS-CoV) [4]. SARS-CoV is one of"/>
  <result pre="enough attention until the outbreak of the severe acute respiratory" exact="syndrome" post="(SARS) coronavirus (SARS-CoV) [4]. SARS-CoV is one of 36"/>
  <result pre="the family Coronaviridae within the order Nidovirales. The demand for" exact="consumption" post="of animal proteins allowed for the transmission from animals"/>
  <result pre="Another member of the family Coronaviridae is the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), which was first reported by Saudi"/>
  <result pre="member of the family Coronaviridae is the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), which was first reported by Saudi Arabia"/>
  <result pre="incubation period of 2 to 14 days, and symptoms include" exact="respiratory" post="and enteric disease. Training and milking of camels have"/>
  <result pre="types of the coronavirus have shown to be a severe" exact="acute" post="respiratory syndrome; however, SARS-CoV-2 has a lower fatality rate"/>
  <result pre="of the coronavirus have shown to be a severe acute" exact="respiratory" post="syndrome; however, SARS-CoV-2 has a lower fatality rate of"/>
  <result pre="be a severe acute respiratory syndrome; however, SARS-CoV-2 has a" exact="lower" post="fatality rate of 2.3%, while SARS-CoV and MERS-CoV have"/>
  <result pre="respectively. The key host for SARS-CoV-2 is bats; however, the" exact="intermediate" post="zoonotic sources need to be identified. The most common"/>
  <result pre="and symptoms for people with COVID-19 are fever and cough." exact="Fever" post="was observed in around 90% of infected patients. A"/>
  <result pre="90% of infected patients. A typical characteristic of COVID-19 is" exact="pneumonia" post="and people have displayed heterogeneous symptoms, such as shortness"/>
  <result pre="such as shortness of breath or dyspnea, as well as" exact="muscle" post="ache. SARS-CoV-2 can be transmitted human-to-human and is mainly"/>
  <result pre="in rare cases [4]. 1.2. Immunity The chain of coronavirus" exact="infection" post="happens when one person infects another and the cycle"/>
  <result pre="a significant proportion of the population has immunity against the" exact="viral" post="or bacterial disease, through what is known as herd"/>
  <result pre="proportion of the population has immunity against the viral or" exact="bacterial disease," post="through what is known as herd immunity [7,8]. This"/>
  <result pre="through vaccination. The same pattern applies to the newly emerging" exact="viral infection," post="COVID-19, due to the spread of the SARS-CoV-2 virus"/>
  <result pre="for COVID-19 is the balance between the natural rate of" exact="disease" post="transmission, and social distancing principles such that the population"/>
  <result pre="been prior attempts to use antimalarial drugs in controlling other" exact="viral" post="infections, including human immunodeficiency virus (HIV) and hepatitis C."/>
  <result pre="use antimalarial drugs in controlling other viral infections, including human" exact="immunodeficiency" post="virus (HIV) and hepatitis C. For example, the antimalarial"/>
  <result pre="controlling other viral infections, including human immunodeficiency virus (HIV) and" exact="hepatitis C." post="For example, the antimalarial drug, ferroquine was proven to"/>
  <result pre="ferroquine was proven to be a strong inhibitor of the" exact="hepatitis C" post="virus, while another antimalarial drug, chloroquine showed weak efficacy"/>
  <result pre="virus, while another antimalarial drug, chloroquine showed weak efficacy against" exact="HIV infection" post="[12,13,14]. Although antimalarial drugs can be effective against a"/>
  <result pre="while another antimalarial drug, chloroquine showed weak efficacy against HIV" exact="infection" post="[12,13,14]. Although antimalarial drugs can be effective against a"/>
  <result pre="Although antimalarial drugs can be effective against a number of" exact="viral" post="infections, their response varies for all viruses and conditions."/>
  <result pre="the treatment of COVID-19. Remdesivir, as an inhibitor of the" exact="viral" post="RNA polymerases, has broad-spectrum activity against SARS-CoV and MERS-CoV"/>
  <result pre="benefits of Remdesivir in improving time to recovery and lowering" exact="respiratory" post="tract infection. However, the trial was implemented in restricted"/>
  <result pre="lack of randomized trials. The interpretation of the results is" exact="limited" post="by the lack of viral load data collection, a"/>
  <result pre="interpretation of the results is limited by the lack of" exact="viral" post="load data collection, a non-uniform duration of therapy, and"/>
  <result pre="This drug was recently shown to be effective against other" exact="viral" post="diseases, including Ebola and the novel coronavirus (SARS-CoV-2) [21]."/>
  <result pre="resulted in a significant decrease in the median time to" exact="viral" post="clearance and faster improvement in patientsâ€™ chest computed tomography"/>
  <result pre="median time to viral clearance and faster improvement in patientsâ€™" exact="chest" post="computed tomography (CT) scans [22]. However, this study was"/>
  <result pre="drug was shown to be a promising candidate for treating" exact="viral" post="diseases, including chikungunya and yellow fever [25]. Several clinical"/>
  <result pre="to be a promising candidate for treating viral diseases, including" exact="chikungunya" post="and yellow fever [25]. Several clinical trials are underway"/>
  <result pre="a promising candidate for treating viral diseases, including chikungunya and" exact="yellow fever" post="[25]. Several clinical trials are underway after Ivermectin was"/>
  <result pre="vitro activity against SARS-CoV-2. Ivermectin led to significant reduction in" exact="viral" post="RNA shortly after treatment [26]. However, the concentrations needed"/>
  <result pre="replication. This phenomenon was observed in many viruses, including the" exact="yellow fever" post="virus, zika virus, and coronaviruses [33]. ADE can adversely"/>
  <result pre="replication of the SARS-CoV virus in infected cells, they granted" exact="viral" post="access to macrophages through ADE, which eventually caused serious"/>
  <result pre="access to macrophages through ADE, which eventually caused serious lung" exact="infections" post="[34,35]. The SARS vaccine candidates resulted in enhanced hepatitis,"/>
  <result pre="virus was shown to utilize the cellular receptors that mimic" exact="viral" post="receptors to gain access to host cells, resulting in"/>
  <result pre="receptors to gain access to host cells, resulting in enhanced" exact="infection" post="[37]. Little is known about whether ADE will present"/>
  <result pre="multiplexing, complexity, throughput, and turnaround times. For example, Genmarkâ€™s ePlex" exact="Respiratory" post="Pathogen instrument can detect common pathogens in the nasopharyngeal"/>
  <result pre="tests with these current devices. With COVID-19 being considered a" exact="respiratory" post="infection, several studies focus on using medical screening lung"/>
  <result pre="medical screening lung scans to track the progress of the" exact="disease" post="in central healthcare infrastructures. One study in Wuhan, China"/>
  <result pre="with and without symptoms of the â€œviral pneumoniaâ€� showed abnormal" exact="chest" post="CTs, specifically as bilateral, subpleural, ground-glass opacities with air"/>
  <result pre="air bronchograms, ill-defined margins, and a slight predominance in the" exact="lower" post="right lobe. As the patient heals, the patientâ€™s lungs"/>
  <result pre="the lungs is via ultrasonography, because the evolution of the" exact="disease" post="can be tracked to inform clinical decision-making. Ultrasounds still"/>
  <result pre="not use radiation and the detection would be repeatable with" exact="lower" post="costs. These techniques should be used to evaluate treatment"/>
  <result pre="necessary precautions that are advised by the CDC [49]. 2.2." exact="Viral" post="Transmission COVID-19 Transmission: The coronavirus spreads primarily through droplets"/>
  <result pre="study on aerosol and surface stability found that SARS-COV-2 was" exact="stable" post="for three hours in its aerosol form [50]. This"/>
  <result pre="its capability to remain viable as an aerosol. While aerosolized" exact="viral" post="particles cannot travel far from an infected patient breathing"/>
  <result pre="wearing a 100% cotton mask, neither mask meaningfully decreased the" exact="viral" post="load coughed onto the Petri dishes [52]. However, surgical"/>
  <result pre="in both droplets and aerosols. The virus was found in" exact="respiratory" post="droplets in 3 out of 10 samples from participants"/>
  <result pre="2b) [53]. There was no detection of any virus in" exact="respiratory" post="droplets or aerosols collected from participants wearing face masks"/>
  <result pre="face masks that showed a trend toward reduced detection in" exact="respiratory" post="droplets with the use of a mask. Thus, surgical"/>
  <result pre="masks reduced the droplets of the virus, but not the" exact="viral" post="load that gets transmitted. To avoid spreading the virus"/>
  <result pre="correlations between temperature and humidity as a function of mean" exact="viral" post="replication rate (Figure 2c) [55]. Optimal temperature and humidity"/>
  <result pre="the demand for PPE grew as healthcare workers started following" exact="infectious disease" post="protocols and as the individuals began shielding themselves from"/>
  <result pre="demand for PPE grew as healthcare workers started following infectious" exact="disease" post="protocols and as the individuals began shielding themselves from"/>
  <result pre="test, the ASTM F 1215-89 particle challenge study, ASTM F2101-01" exact="bacterial" post="filtration efficiency (BFE), Mil- M369454C breathability, and CPSC CS-191-53"/>
  <result pre="it might not be able to safely provide fluid resistance," exact="bacterial" post="filtration, and breathability. Moreover, 3D-printed PPE may not be"/>
  <result pre="face shields are not a fool-proof method of protection against" exact="viral" post="particles, a short-term barrier is sustained against the exposure"/>
  <result pre="particles, a short-term barrier is sustained against the exposure of" exact="respiratory" post="droplets by 97% after five minutes, and 81% after"/>
  <result pre="also designed HappyShield, which is a curved-crease origami face-shield for" exact="infection" post="control [70]. HappyShield can be easily assembled on-site and"/>
  <result pre="can carry microorganisms and will lead to increased rates of" exact="infection" post="among both patients and medical professionals. For non-medical settings,"/>
  <result pre="factors associated with using mechanical ventilation in different patient age-groups," exact="disease" post="stages, and disease severities. 2.6. Machine Learning Analysis of"/>
  <result pre="using mechanical ventilation in different patient age-groups, disease stages, and" exact="disease" post="severities. 2.6. Machine Learning Analysis of COVID-19 Machine Learning"/>
  <result pre="the COVID-19 pandemic, such as molecular, clinical, and societal utilization." exact="Protein" post="structure prediction for COVID-19 Drug Design: From a molecular"/>
  <result pre="to better understand the proteins that are involved in SARS-CoV-2" exact="infection" post="to help the search for potential targets for treatment."/>
  <result pre="First, an AlphaFold [83] model was used to predict the" exact="Protein" post="3D structure that was determined by amino acid sequences"/>
  <result pre="methods that are both accurate and rapid to combat the" exact="disease" post="using machine learning to support diagnosis from CT scans"/>
  <result pre="automatic screening and diagnosis of COVID-19 detection, based on CT" exact="chest" post="scans [86]. The inputs are pre-processed CT pictures from"/>
  <result pre="fed into a 3D deep neural network and predicts the" exact="infection" post="rate. Taking 3D space information for a weakly-supervised deep-learning"/>
  <result pre="information for a weakly-supervised deep-learning model improved the prediction for" exact="infection" post="(Figure 5b). Pandemic Predictions for Hospitalizations: To prepare, plan,"/>
  <result pre="hospitalization should be identified to calculate the probability of developing" exact="acute" post="respiratory distress and organ failure during clinic treatments. Based"/>
  <result pre="should be identified to calculate the probability of developing acute" exact="respiratory" post="distress and organ failure during clinic treatments. Based on"/>
  <result pre="can identify patients at high risk and who might develop" exact="respiratory" post="distress in the future. Using models such as Gradient"/>
  <result pre="countries around the world have been trying to overcome the" exact="disease" post="over the past few months by extensive testing and"/>
  <result pre="of China (NHC), the COVID Tracking Project, European Centre for" exact="Disease" post="Prevention and Control (ECDC), and CDC. Notable websites on"/>
  <result pre="is therefore harder to track and to control its spread." exact="Epidemic" post="curves are often plotted in an attempt to understand"/>
  <result pre="often plotted in an attempt to understand the extent of" exact="infections" post="and the implications of preventative measures. The CDC suggested"/>
  <result pre="models work (Figure 6c). Hospital Resource Predictions: The Institute for" exact="Disease" post="Modeling produced software called Epidemiological Modeling (EMOD) [90], which"/>
  <result pre="it down. Utilizing mathematical basis and concepts, factors such as" exact="susceptibility to" post="disease, cases which tested positive for COVID-19, and cases"/>
  <result pre="helps in the analysis of how prevention of the COVID-19" exact="infection" post="could have been brought about by implementing control measures."/>
  <result pre="environment that exists on the â€œDiamond Princessâ€� cruise ship, a" exact="disease" post="transmission model based on crowd flow control would be"/>
  <result pre="to run experiments that would take months or years to" exact="complete" post="on a traditional computing platform at a faster pace."/>
  <result pre="computers to allow researchers to run projects related to the" exact="disease" post="which require high computing power [93]. This consortium includes"/>
  <result pre="structure of the virus at the molecular level, analyzing the" exact="viral" post="RNA, studying the DNA of the patients infected, and"/>
  <result pre="the St. Louis School of Medicine [96]. It focuses on" exact="disease" post="research, connecting the unused processing power of laptops and"/>
  <result pre="the Ebola virus, uncovering a previously unknown structure of the" exact="viral" post="protein with a druggable site [97]. Rosetta@Home is another"/>
  <result pre="University of Washington, to predict the three-dimensional shapes of the" exact="viral" post="proteins in their final folded state [98]. Unlike Folding@Home"/>
  <result pre="of the proteins in the fight against the virus. 2.8." exact="Digital" post="Monitoring Social Contract Tracing: In the past few months,"/>
  <result pre="tracing has been implemented in many places to contain the" exact="disease" post="while allowing people to live a new normal [99]."/>
  <result pre="of infection. The government can use this information to recognize" exact="infection" post="hotspots and come up with strategies. This process is"/>
  <result pre="[113], which identifies people who are at risk of COVID-19" exact="infection" post="in an anonymous and location-independent manner by using Bluetooth"/>
  <result pre="Tracking: Another method of digitally monitoring the spread of the" exact="disease" post="involves studying online search behavior [114]. A study by"/>
  <result pre="viruses, virus-like particles, protein nanoparticles in matrix-M, non-replicating or replicating" exact="viral" post="vectors, RNA- or DNA-based vaccines, and protein subunits. Along"/>
  <result pre="under clinical trials are an mRNA vaccine and a non-replicating" exact="viral" post="vector vaccine [116]. The University of Oxford is using"/>
  <result pre="vaccine [116]. The University of Oxford is using a non-replicating" exact="viral" post="vector from chimpanzeesâ€™ adenovirus to target the S glycoprotein,"/>
  <result pre="so ensures that we have a better understanding of the" exact="disease" post="progression and can further help in allocating medical staff"/>
  <result pre="variability in the reported data and are uninformative about the" exact="disease" post="progression, which negatively affects several nationsâ€™ ability to adequately"/>
  <result pre="testing checks for the presence of SARS-CoV-2 genetic material from" exact="respiratory" post="specimens, either through swapping nostrils or sampling saliva. In"/>
  <result pre="which would be critical to assigning citizens the immunity passport." exact="Antibody" post="tests still need to have acceptable specificities and sensitivities,"/>
  <result pre="needed to deal with the sudden influx of patients. Many" exact="primary" post="care doctors are working remotely via telemedicine and can"/>
  <result pre="hospitals and clinics to provide services in environments with high" exact="viral" post="exposure, coupled with a lack of PPE. Most countries"/>
  <result pre="its trajectory. The role of public regulations in controlling the" exact="disease" post="infection rate was shown, with specific emphasis on standardizing"/>
  <result pre="trajectory. The role of public regulations in controlling the disease" exact="infection" post="rate was shown, with specific emphasis on standardizing the"/>
  <result pre="References 1.GuoL.RenL.YangS.XiaoM.ChangD.YangF.CruzC.S.D.WangY.WuC.XiaoY.et al.Profiling Early Humoral Response to Diagnose Novel Coronavirus" exact="Disease" post="(COVID-19)Clin. Infect. Dis.202010.1093/cid/ciaa31032198501 2.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, Evaluation and Treatment Coronavirus"/>
  <result pre="Coronavirus that Causes a Global ThreatInt. J. Biol. Sci.2020161678168510.7150/ijbs.4505332226285 5.ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.-Y.Severe" exact="Acute" post="Respiratory Syndrome Coronavirus as an Agent of Emerging and"/>
  <result pre="that Causes a Global ThreatInt. J. Biol. Sci.2020161678168510.7150/ijbs.4505332226285 5.ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.-Y.Severe Acute" exact="Respiratory" post="Syndrome Coronavirus as an Agent of Emerging and Reemerging"/>
  <result pre="Causes a Global ThreatInt. J. Biol. Sci.2020161678168510.7150/ijbs.4505332226285 5.ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.-Y.Severe Acute Respiratory" exact="Syndrome" post="Coronavirus as an Agent of Emerging and Reemerging InfectionClin."/>
  <result pre="Agent of Emerging and Reemerging InfectionClin. Microbiol. Rev.20072066069410.1128/CMR.00023-0717934078 6.RamadanN.ShaibH.Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): A reviewGerms20199354210.18683/germs.2019.115531119115 7.FineP.EamesK.HeymannD.L.â€œHerd Immunityâ€�: A Rough"/>
  <result pre="of Emerging and Reemerging InfectionClin. Microbiol. Rev.20072066069410.1128/CMR.00023-0717934078 6.RamadanN.ShaibH.Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): A reviewGerms20199354210.18683/germs.2019.115531119115 7.FineP.EamesK.HeymannD.L.â€œHerd Immunityâ€�: A Rough GuideClin."/>
  <result pre="Res.202017710476210.1016/j.antiviral.2020.10476232147496 11.MahÃ©vasM.TranV.-T.RoumierM.ChabrolA.PauleR.GuillaudC.FoisE.LepeuleR.SzwebelT.-A.LescureF.-X.et al.Clinical efficacy of hydroxychloroquine in patients with covid-19" exact="pneumonia" post="who require oxygen: Observational comparative study using routine care"/>
  <result pre="using routine care dataBMJ202036910.1136/bmj.m1844 12.Dâ€™AlessandroS.ScaccabarozziD.SignoriniL.PeregoF.IlboudoD.P.FerranteP.DelbueS.The Use of Antimalarial Drugs against" exact="Viral" post="InfectionMicroorganisms202088510.3390/microorganisms8010085 13.VausselinT.CallandN.BelouzardS.DescampsV.DouamF.HelleF.FrancoisC.LavilletteD.DuverlieG.WahidA.et al.The antimalarial ferroquine is an inhibitor of"/>
  <result pre="Viral InfectionMicroorganisms202088510.3390/microorganisms8010085 13.VausselinT.CallandN.BelouzardS.DescampsV.DouamF.HelleF.FrancoisC.LavilletteD.DuverlieG.WahidA.et al.The antimalarial ferroquine is an inhibitor of" exact="hepatitis C" post="virusHepatology201358869710.1002/hep.2627323348596 14.NeelyM.KalyesubulaI.BagendaD.MyersC.OlnessK.Effect of chloroquine on human immunodeficiency virus (HIV)"/>
  <result pre="inhibitor of hepatitis C virusHepatology201358869710.1002/hep.2627323348596 14.NeelyM.KalyesubulaI.BagendaD.MyersC.OlnessK.Effect of chloroquine on human" exact="immunodeficiency" post="virus (HIV) vertical transmissionAfr. Health Sci.20033616712913796 15.Clinical Trial Launches"/>
  <result pre="J. Med.202010.1056/NEJMoa200776432445440 17.GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.FeldtT.GreenG.GreenM.L.LescureF.-X.et al.Compassionate Use of Remdesivir for Patients with" exact="Severe" post="Covid-19N. Engl. J. Med.20203822327233610.1056/NEJMoa200701632275812 18.ShirakiK.DaikokuT.Favipiravir, an anti-influenza drug against"/>
  <result pre="virus infectionsPharmacol. Ther.202020910751210.1016/j.pharmthera.2020.10751232097670 19.FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Jpn. Acad. Ser. B20179344946310.2183/pjab.93.02728769016 20.DelangL.AbdelnabiR.NeytsJ.Favipiravir as a"/>
  <result pre="USA2020 25.VargheseF.KaukinenP.GlÃ¤skerS.BespalovM.HanskiL.WennerbergK.KÃ¼mmererB.M.AholaT.Discovery of berberine, abamectin and ivermectin as antivirals against" exact="chikungunya" post="and other alphavirusesAntivir. Res.201612611712410.1016/j.antiviral.2015.12.01226752081 26.CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug ivermectin inhibits"/>
  <result pre="Enhancement of Coronavirus EntryJ. Virol.2019949410.1128/JVI.02015-1931826992 34.LiuL.WeiQ.LinQ.FangJ.WangH.KwokH.TangH.NishiuraK.PengJ.TanZ.et al.Anti-spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARS-CoV"/>
  <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARS-CoV infectionJCI Insight2019410.1172/jci.insight.123158 35.Antibody-Dependent Enhancement of SARS Coronavirus Infection"/>
  <result pre="during acute SARS-CoV infectionJCI Insight2019410.1172/jci.insight.123158 35.Antibody-Dependent Enhancement of SARS Coronavirus" exact="Infection" post="and Its Role in the Pathogenesis of SARSAvailable online:"/>
  <result pre="online: https://www.hkmj.org/abstracts/v22n3%20Suppl%204/25.htm(accessed on 13 June 2020) 36.WeingartlH.CzubM.CzubS.NeufeldJ.MarszalP.GrenJ.SmithG.JonesS.ProulxR.DeschambaultY.et al.Immunization with Modified" exact="Vaccinia" post="Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome"/>
  <result pre="36.WeingartlH.CzubM.CzubS.NeufeldJ.MarszalP.GrenJ.SmithG.JonesS.ProulxR.DeschambaultY.et al.Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against" exact="Severe" post="Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in"/>
  <result pre="al.Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe" exact="Acute" post="Respiratory Syndrome Is Associated with Enhanced Hepatitis in FerretsJ."/>
  <result pre="with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute" exact="Respiratory" post="Syndrome Is Associated with Enhanced Hepatitis in FerretsJ. Virol.200478126721267610.1128/JVI.78.22.12672-12676.200415507655"/>
  <result pre="Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory" exact="Syndrome" post="Is Associated with Enhanced Hepatitis in FerretsJ. Virol.200478126721267610.1128/JVI.78.22.12672-12676.200415507655 37.HouserK.V.BroadbentA.J.GretebeckL.VogelL.LamirandeE.W.SuttonT.BockK.W.MinaiM.OrandleM.MooreI.N.et"/>
  <result pre="Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced" exact="Hepatitis" post="in FerretsJ. Virol.200478126721267610.1128/JVI.78.22.12672-12676.200415507655 37.HouserK.V.BroadbentA.J.GretebeckL.VogelL.LamirandeE.W.SuttonT.BockK.W.MinaiM.OrandleM.MooreI.N.et al.Enhanced inflammation in New Zealand"/>
  <result pre="New Zealand white rabbits when MERS-CoV reinfection occurs in the" exact="absence of" post="neutralizing antibodyPLoS Pathog.201713e100656510.1371/journal.ppat.100656528817732 38.TetroJ.A.Is COVID-19 receiving ADE from other"/>
  <result pre="12 May 2020) 42.Radiological Findings from 81 Patients with COVID-19" exact="Pneumonia" post="in Wuhan, China: A Descriptive Study-The Lancet Infectious DiseasesAvailable"/>
  <result pre="with COVID-19 Pneumonia in Wuhan, China: A Descriptive Study-The Lancet" exact="Infectious" post="DiseasesAvailable online: https://www.thelancet.com/article/S1473-3099(20)30086-4/fulltext(accessed on 12 May 2020) 43.LabCorp, Quest"/>
  <result pre="online: https://www.thelancet.com/article/S1473-3099(20)30086-4/fulltext(accessed on 12 May 2020) 43.LabCorp, Quest Expand COVID-19" exact="Antibody" post="Testing NationwideAvailable online: https://www.medtechdive.com/news/labcorp-quest-expand-covid-19-antibody-testing-nationwide/576884/(accessed on 12 May 2020) 44.Corrales-AguilarE.TrillingM.ReinhardH.FalconeV.ZimmermannA.AdamsO.SantibanezS.HengelH.Highly"/>
  <result pre="from University of Washington Demonstrates High Performance of Abbottâ€™s SARS-CoV-2" exact="Antibody" post="Blood Test-8 May 2020Available online: https://abbott.mediaroom.com/2020-05-08-Research-from-University-of-Washington-Demonstrates-High-Performance-of-Abbotts-SARS-CoV-2-Antibody-Blood-Test(accessed on 12 May"/>
  <result pre="University of Washington Demonstrates High Performance of Abbottâ€™s SARS-CoV-2 Antibody" exact="Blood" post="Test-8 May 2020Available online: https://abbott.mediaroom.com/2020-05-08-Research-from-University-of-Washington-Demonstrates-High-Performance-of-Abbotts-SARS-CoV-2-Antibody-Blood-Test(accessed on 12 May 2020)"/>
  <result pre="on 12 May 2020) 46.UW Starts Testing People with COVID" exact="Antibody" post="Test That Boasts Nearly 100% AccuracyAvailable online: https://www.kiro7.com/news/local/uw-starts-testing-people-with-covid-antibody-test-that-boasts-nearly-100-accuracy/RFCEDOCPVJEWPMYKUVSEVRRPYQ/(accessed on"/>
  <result pre="12 May 2020) 47.Abbott Launches Third COVID-19 Test, A Laboratory-Based" exact="Antibody" post="Blood Test That Will Ship in the U.S. Starting"/>
  <result pre="May 2020) 47.Abbott Launches Third COVID-19 Test, A Laboratory-Based Antibody" exact="Blood" post="Test That Will Ship in the U.S. Starting Tomorrow-15"/>
  <result pre="toolmedRxiv202010.1101/2020.03.26.20044727 56.In Response to COVID-19: A Technique to Improve the" exact="Viral" post="Protection of a Dental Procedure Mask in Absence of"/>
  <result pre="Improve the Viral Protection of a Dental Procedure Mask in" exact="Absence of" post="an N95 Shield RespiratorAvailable online: https://www.perioimplantadvisory.com/periodontics/oral-medicine-anesthetics-and-oral-systemic-connection/article/14173091/in-response-to-covid19-a-technique-to-improve-the-viral-protection-of-a-dental-procedure-mask-in-absence-of-an-n95-shield-respirator(accessed on 12 May"/>
  <result pre="HEPA FiltersAvailable online: https://www.hamilton-medical.com/en_EG/E-Learning-and-Education/Knowledge-Base/Knowledge-Base-Detail~2020-03-18~Efficiency-of-HEPA-filters~d5358f88-753e-4644-91c6-5c7b862e941f~.html#DataTables_Table_0=od3(accessed on 12 May 2020) 60.collab: CDCCoronavirus" exact="Disease" post="2019 (COVID-19)Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/face-masks.html(accessed on 12 May 2020) 61.Good"/>
  <result pre="in the COVID-19 Crisis3D Print. Addit. Manuf.20207979910.1089/3dp.2020.0101 64.RobergeR.J.Face shields for" exact="infection" post="control: A reviewJ. Occup. Environ. Hyg.20161323524210.1080/15459624.2015.109530226558413 65.LindsleyW.G.NotiJ.D.BlachereF.M.SzalajdaJ.V.BeezholdD.Efficacy of face"/>
  <result pre="2020) 86.YanL.ZhangH.-T.XiaoY.WangM.SunC.LiangJ.LiS.ZhangM.GuoY.XiaoY.et al.Prediction of criticality in patients with severe Covid-19" exact="infection" post="using three clinical features: A machine learning-based prognostic model"/>
  <result pre="Weak LabelmedRxiv202010.1101/2020.03.12.20027185 88.DandekarR.BarbastathisG.Quantifying the effect of quarantine control in Covid-19" exact="infectious" post="spread using machine learningmedRxiv202010.1101/2020.04.03.20052084 89.HuZ.GeQ.LiS.JinL.XiongM.Artificial Intelligence Forecasting of Covid-19"/>
  <result pre="2020) 94.SmithM.SmithJ.C.Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2" exact="Viral" post="Spike Protein and Viral Spike Protein-Human ACE2 InterfaceChemRxiv202010.26434/chemrxiv.11871402.v4 95.PostEra|COVID-19Available"/>
  <result pre="Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike" exact="Protein" post="and Viral Spike Protein-Human ACE2 InterfaceChemRxiv202010.26434/chemrxiv.11871402.v4 95.PostEra|COVID-19Available online: https://covid.postera.ai/covid(accessed"/>
  <result pre="COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and" exact="Viral" post="Spike Protein-Human ACE2 InterfaceChemRxiv202010.26434/chemrxiv.11871402.v4 95.PostEra|COVID-19Available online: https://covid.postera.ai/covid(accessed on 12"/>
  <result pre="ACE2 InterfaceChemRxiv202010.26434/chemrxiv.11871402.v4 95.PostEra|COVID-19Available online: https://covid.postera.ai/covid(accessed on 12 May 2020) 96.Folding@homeâ€&quot;Fighting" exact="Disease" post="with a World Wide distributed super computerAvailable online: https://foldingathome.org/(accessed"/>
  <result pre="using simulations and experimentsbioRxiv202010.1101/2020.02.09.940510 98.Rosettaâ€™s role in fighting coronavirusâ€&quot;Institute for" exact="Protein" post="DesignAvailable online: https://www.ipd.uw.edu/2020/02/rosettas-role-in-fighting-coronavirus/(accessed on 12 May 2020) 99.ChoH.IppolitoD.YuY.W.Contact Tracing"/>
  <result pre="Phase 3 Trial of Investigational Antiviral Remdesivir in Patients with" exact="Severe" post="COVID-19Available online: https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19(accessed on 12 May 2020) 135.Sanofi and"/>
  <result pre="for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2" exact="Infection" post="and Identify Potential Prognostic Biomarkers|Merck Newsroom HomeAvailable online: https://www.mrknewsroom.com/news-release/research-and-development-news/merck-and-institute-systems-biology-collaborate-define-mo(accessed"/>
  <result pre="are a potential natural reservoir, and other intermediates facilitate the" exact="infection" post="of coronavirus to humans. Human-to-human transmission is a common"/>
  <result pre="is a common characteristic in three types of coronaviruses, severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, and Middle East respiratory"/>
  <result pre="a common characteristic in three types of coronaviruses, severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), SARS-CoV-2, and Middle East respiratory syndrome"/>
  <result pre="common characteristic in three types of coronaviruses, severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), SARS-CoV-2, and Middle East respiratory syndrome coronavirus"/>
  <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). Even though the fatality rate is"/>
  <result pre="acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). Even though the fatality rate is not"/>
  <result pre="syndrome coronavirus (MERS-CoV). Even though the fatality rate is not" exact="lower" post="than SARS-CoV and MERS-CoV, vaccines and treatments are needed;"/>
  <result pre="infected patients to any susceptible individual, resulting in a high" exact="infection" post="rate and high mortality. On the other hand, herd"/>
  <result pre="centers use samples from nasopharyngeal swabs and test for COVID-19" exact="infection" post="via molecular or reverse transcription-polymerase chain reaction (RT-PCR) tests,"/>
  <result pre="in the air; (b) The difference in the spread of" exact="viral" post="load and aerosol droplets with a mask and without"/>
  <result pre="masks are to be used by healthcare workers in the" exact="absence of" post="N95 respirators; (c) The regular method for tying surgical"/>
  <result pre="a bag-valve-mask to administer air (left). The National Aeronautics and" exact="Space" post="Administration (NASA) VITAL uses sensors and a mechanical pump"/>
  <result pre="ventilators are termed â€œbridgeâ€� ventilators and are intended for an" exact="intermediate" post="use between hospitalized patients and critically ill patients. â€œBridgeâ€�"/>
  <result pre="condition. Figure 5 Machine learning analysis of COVID-19 dynamics. (a)" exact="Protein" post="unfolding prediction. The first step is a multiple sequence"/>
  <result pre="the comparison of mortality cases related to COVID-19, influenza, and" exact="pneumonia" post="in the US, as visualized by the CDC; (i)"/>
  <result pre="metrics that predicts the severity of COVID-19 spread. Figure 7" exact="Digital" post="monitoring tools of COVID-19 spread by online and cellphone"/>
  <result pre="tools of COVID-19 spread by online and cellphone applications. (a)" exact="General" post="smartphone app-based contact tracingâ€&quot;the social encounters (distance less than"/>
  <result pre="the symptoms of users to monitor the prevalence of the" exact="disease" post="and identify potential hotspots: screenshots from a generic symptom"/>
  <result pre="to show sample survey questions, COVID Symptom Study (by Massachusetts" exact="General" post="Hospital, the Harvard T.H. Chan School of Public Health,"/>
  <result pre="and testing current medications [131] Eli Lilly Treatment Adopting its" exact="rheumatoid arthritis" post="therapy (Baricitinib) and other antibody therapies for COVID-19 [132]"/>
  <result pre="testing current medications [131] Eli Lilly Treatment Adopting its rheumatoid" exact="arthritis" post="therapy (Baricitinib) and other antibody therapies for COVID-19 [132]"/>
  <result pre="COVID-19 vaccine using mRNA technology [139] Novartis Prevention Adopting its" exact="autoimmune disease" post="therapy (Canakinumab) for COVID-19 [140] Roche Diagnostics and Treatment"/>
  <result pre="vaccine using mRNA technology [139] Novartis Prevention Adopting its autoimmune" exact="disease" post="therapy (Canakinumab) for COVID-19 [140] Roche Diagnostics and Treatment"/>
 </snippets>
</snippetsTree>
